Financial targets

Immunovia has adopted the following financial targets (link to press release):

  • Immunovia’s targets to achieve a turnover of SEK 250-300 million in 2021 based on self-pay for IMMray™ PanCan-d.
  • Immunovia targets further to achieve a total turnover, for self-pay and reimbursement, of SEK 800-1,000 million in 2023.

Immunovia’s financial targets set forth above constitute forward-looking information and are based on a number of assumptions about the environment in which the Company operates, which may vary significantly and deteriorate over time from what Immunovia assessed when the financial targets were adopted. As a consequence, Immunovia’s ability to achieve the financial targets consists of uncertainties and contingencies, some of which are outside the Company’s control. There is no guarantee that Immunovia can achieve the financial targets or that Immunovia’s financial position or operating profit will not differ materially from the financial targets.


Subscribe to receive press releases and reports via email
To start your subscription you need to activate your e-mail address by clicking the link in the email that is sent to you after you have submitted this form.

Press releases
Financial reports